**TABLE 1** Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

|  |  |  |  |
| --- | --- | --- | --- |
|  | Placebo group | Troglitazone group | P |
| *N* | 122 | 114 |  |
| Clinical characteristics |  |  |  |
|  | Age (years)  | 34.3  | ± 6.5 | 34.9  | ± 6.6 | 0.52 |
|  | BMI (kg/m2) | 30.3  | ± 5.3 | 30.6  | ± 6.1 | 0.63 |
|  | Waist-to-hip circumference ratio  | 0.86  | ± 0.05 | 0.85  | ± 0.06 | 0.19 |
|  | Using hormonal contraceptives\*  | 48% | 43% | 0.41 |
| OGTT† |  |  |  |  |  |
|  | Fasting glucose (mg/dl) | 98.1  | ± 9.1 | 98.7  | ± 10.2 | 0.64 |
| 2-h glucose | 154.0  | ± 24.0 | 154.4  | ± 27.0 | 0.97 |
|  | Total glucose area (mg/dl x min x 103)‡ | 18.7  | ± 2.0 | 18.9  | ± 2.0 | 0.25 |
|  | Impaired glucose tolerance§ | 72% | 69% | 0.66 |
|  | Fasting insulin (µU/ml) 16.0 | 16.0  | ± 7.5 | 17.0  | ± 10.8 | 0.82 |
|  | Total insulin area (µU/ml x min)‡ | 10,209  | ± 5536 | 9,902  | ± 6543 | 0.55 |
| IVGTT |  |  |  |  |  |
|  | Fasting glucose (mg/dl)  | 94.3  | ± 10.4 | 94.8  | ± 10.2 | 0.71 |
|  | *Kg* (min-1 x 100)¶ | 1.48  | ± 0.40 | 1.42  | ± 0.39 | 0.23 |
|  | Fasting insulin (µU/ml)  | 18.7  | ± 9.7 | 16.6  | ± 9.5 | 0.05 |
|  | *S****I*** (min-1 per µU/ml x 104)# | 2.28  | ± 1.75 | 2.64  | ± 1.70 | 0.05 |
|  | AIRg (µU/ml x min)\*\* | 569  | ± 527 | 454  | ± 360 | 0.18 |
|  | Total insulin area (units/ml x min)‡ | 10,686  | ± 5686 | 9,273  | ± 5434 | 0.03 |
|  | DI (*SI* x AIRg)† | 983  | ± 697 | 976  | ± 717 | 0.99 |